Napatree Capital LLC Invests $445,000 in Organon & Co. (NYSE:OGN)

Napatree Capital LLC purchased a new stake in Organon & Co. (NYSE:OGN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 29,854 shares of the company's stock, valued at approximately $445,000.

Several other large investors have also modified their holdings of OGN. Barclays PLC lifted its stake in Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company's stock valued at $2,285,000 after buying an additional 84,136 shares in the last quarter. Weiss Asset Management LP purchased a new stake in shares of Organon & Co. in the third quarter valued at $32,966,000. Cerity Partners LLC boosted its stake in shares of Organon & Co. by 94.0% during the third quarter. Cerity Partners LLC now owns 667,340 shares of the company's stock valued at $12,766,000 after acquiring an additional 323,308 shares during the last quarter. Robeco Institutional Asset Management B.V. acquired a new stake in shares of Organon & Co. during the fourth quarter valued at $2,263,000. Finally, Victory Capital Management Inc. increased its position in Organon & Co. by 127.3% during the 3rd quarter. Victory Capital Management Inc. now owns 183,298 shares of the company's stock worth $3,506,000 after purchasing an additional 102,663 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

OGN has been the topic of a number of recent research reports. Barclays reduced their target price on shares of Organon & Co. from $26.00 to $24.00 and set an "overweight" rating on the stock in a report on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research note on Wednesday, January 15th. Finally, Morgan Stanley lowered their target price on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating for the company in a research note on Friday, February 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $20.80.

Remove Ads

Organon & Co. Trading Down 1.0 %

Shares of OGN traded down $0.15 during mid-day trading on Thursday, hitting $14.57. The company had a trading volume of 2,356,064 shares, compared to its average volume of 2,424,234. Organon & Co. has a 1-year low of $13.87 and a 1-year high of $23.10. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The business's 50-day simple moving average is $15.36 and its 200-day simple moving average is $16.30. The stock has a market cap of $3.76 billion, a PE ratio of 4.37, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. Sell-side analysts forecast that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were paid a dividend of $0.28 per share. The ex-dividend date was Monday, February 24th. This represents a $1.12 annualized dividend and a yield of 7.69%. Organon & Co.'s dividend payout ratio is presently 33.63%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.